Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.
Interventions
DRUGrepaglinide
Dose individually adjusted and conducted according to labeling
DRUGglyburide
Dose individually adjusted and conducted according to labeling
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%) * Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%) * Males or non-pregnant, non-lactating females * Subjects should have normal renal function
Exclusion criteria
* Type 1 or other specific causes of diabetes * Marked symptomatic diabetes * Uncontrolled treated/untreated hypertension * Known or suspected allergy to the trial products or related products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglyceride levels post standardised fat tolerance test | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of hypoglycemic episodes | — |
| Change in HbA1c (glycosylated haemoglobin A1c) | — |
| Change in FPG (fasting plasma glucose) | — |
Countries
United States
Outcome results
None listed